title: Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields.
abstract: A 54 year-old woman was diagnosed with multiple sclerosis (MS) in 1985 at the age of 45 after she developed diplopia, slurred speech, and weakness in the right leg. A Magnetic Resonance Imaging (MRI) scan obtained in 1985 showed several areas of plaque formation distributed in the periventricular white matter and centrum semiovale bilaterally. Coincident with slow deterioration in her condition since 1990 a second MRI scan was obtained in 1991 which showed a considerable increase in the number and size of plaques throughout both cerebral hemispheres, subcortical white matter, periventricularly and brainstem. In 1994, the patient received treatment with Interferon beta- 1b (Betaseron) for 6 months with no improvement in symptoms. However, following two successive extracranial applications of pulsed electromagnetic fields (EMFs) in the picotesla (pT) range each of 20 minutes duration the patient experienced an immediate improvement in symptoms most dramatically in gait, balance, speech, level of energy, swallowing, mood, and vision. On a maintenance program of 3 treatments per month the patient's only symptom is mild right foot and leg weakness. The report points to the unique efficacy of externally applied pT range EMFs in the symptomatic treatment of MS, indicates a lack of an association between the extent of demyelinating plaques on MRI scan and rate and extent of recovery in response to EMFs, and supports the notion that dysfunction of synaptic conductivity due to neurotransmitter deficiency particularly of serotonin (5-HT) contributes more significantly to the development of MS symptoms than the process of demyelination which clinically seems to represent an epiphenomenon of the disease.
authors.affiliation: NeuroCommunication Research Laboratories, Danbury, CT 06811, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sandyk
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology*; D003711:Demyelinating Diseases / Q000503:physiopathology; D004574:Electromagnetic Fields; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008550:Melatonin / Q000378:metabolism; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy*; D010870:Pineal Gland / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068576:Interferon beta-1b; D012701:Serotonin; D016899:Interferon-beta; D008550:Melatonin; D000068556:Interferon beta-1a